Boston Scientific Corporation $BSX Shares Acquired by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 3.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,870 shares of the medical equipment provider’s stock after buying an additional 1,586 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Boston Scientific were worth $4,819,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Wealthstar Advisors LLC grew its position in shares of Boston Scientific by 13.8% during the second quarter. Wealthstar Advisors LLC now owns 6,838 shares of the medical equipment provider’s stock worth $734,000 after buying an additional 830 shares in the last quarter. 3Chopt Investment Partners LLC acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $208,000. IFP Advisors Inc grew its position in shares of Boston Scientific by 31.9% during the second quarter. IFP Advisors Inc now owns 21,988 shares of the medical equipment provider’s stock worth $2,372,000 after buying an additional 5,313 shares in the last quarter. Callan Family Office LLC grew its position in shares of Boston Scientific by 294.7% during the second quarter. Callan Family Office LLC now owns 28,397 shares of the medical equipment provider’s stock worth $3,050,000 after buying an additional 21,203 shares in the last quarter. Finally, Blair William & Co. IL grew its position in shares of Boston Scientific by 0.7% during the second quarter. Blair William & Co. IL now owns 118,768 shares of the medical equipment provider’s stock worth $12,757,000 after buying an additional 826 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on BSX shares. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Evercore ISI lowered their target price on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday. BTIG Research boosted their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday. Finally, Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $120.71.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $97.28 on Friday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a market cap of $144.14 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a fifty day moving average of $102.18 and a 200-day moving average of $101.92.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.